A cost-consequences analysis of the effect of pregabalin in the treatment of painful radiculopathy under medical practice conditions in primary care settings

Pain Practice

Volumn 10, Issue 1, 2010, Pages 31-41

  Saldaña, María T ^a   Navarro, Ana ^b   Pérez, Concepción ^c   Masramón, Xavier ^d   Rejas, Javier ^e  

^a Raíces Primary Care Center   (Spain)

^b Puerta Del Ángel Primary Care Center   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d European Biometrics Institute   (Spain)

^e PFIZER INC   (United States)

Author keywords

Consequences; Cost; Health care resources; Pain; Pregabalin; Productivity; Radiculopathy

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CYANOCOBALAMIN; DICLOFENAC; DIPYRONE; IBUPROFEN; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PREGABALIN; PYRIDOXINE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT;

ABSENTEEISM; ADD ON THERAPY; ADULT; ARTICLE; COST CONTROL; DRUG WITHDRAWAL; FEMALE; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MCGILL PAIN QUESTIONNAIRE; PRIMARY MEDICAL CARE; RADICULOPATHY; UNSPECIFIED SIDE EFFECT;

EID: 77249095879     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2009.00312.x     Document Type: Article

References (38)

1. IASP Task Force in Taxonomy. Pain terms: a current list with definitions and notes on usage. In: Merksey H, Bogduk N, eds. Classification of Chronic Pain Syndromes and Definitions of Pain Terms. 2nd ed. Seattle, Washington: IASP Press;1994:206-213.
2. Smith BH, Torrance N, Bennett MI, Lee AJ. Health and quality of life associated with chronic pain of predominantly neuropathic origin in the community. Clin J Pain. 2007;23:143-149.
3. Fishbain DA, Lewis JE, Cutler R, Cole B, Rosomoff HL, Rosomoff RS. Can the neuropathic pain scale discriminate between non-neuropathic and neuropathic pain? Pain Med. 2008;9:149-160.
4. Treede RD, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70:1630-1635.
5. Argoff CE. The coexistence of neuropathic pain, sleep, and psychiatric disorders: a novel treatment approach. Clin J Pain. 2007;23:15-22.
6. Gore M, Brandenburg NA, Dukes E, Hoffman DL, Tai KS, Stacey B. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage. 2005;30:374-385.
7. McDermott AM, Toelle TR, Rowbotham DJ, Schaefer CP, Dukes EM. The burden of neuropathic pain: results from a cross-sectional survey. Eur J Pain. 2006; 10:127-135.
8. Harden N, Cohen M Unmet needs in the management of neuropathic pain. J Pain Symptom Manage. 2003; 25(suppl 5):S12-S17.
9. Rodríguez MJ, García AJ. A registry of the aetiology and costs of neuropathic pain in pain clinics: results of the registry of a etiologies and costs (REC) in neuropathic pain disorders study. Clin Drug Invest. 2007;27:771-782.
10. Tolle T, Dukes E, Sadosky A. Patient burden of trigeminal neuralgia: results from a cross-sectional survey of health state impairment and treatment patterns in six European countries. Pain Pract. 2006;6:153-160.
11. Tassone DM, Boyce E, Guyer J, Nuzum D. Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther. 2007;29:26-48.
12. Vranken JH, Dijkgraaf MG, Kruis MR, van der Vegt MH, Hollmann MW, Heesen M. Pregabalin in patients with central neuropathic pain: a randomized, double-blind, placebo-controlled trial of a flexible-dose regimen. Pain. 2008;136:150-157.
13. Nymdelger S, Nieber K. Pregabalin-a neuromodulator for the treatment of neuropathic pain, generalized anxiety disorders and fibromyalgia syndrome. Med Monatsschr Pharm. 2007;30:396-400.
14. Freynhagen R, Grond S, Schüpfer G, et al. Efficacy and safety of pregabalin in treatment refractory patients with various neuropathic pain entities in clinical routine. Int J Clin Pract. 2007;61:1989-1996.
15. Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain. 2005;115:254-263.
16. Tölle T, Freynhagen R, Versavel M, Trostmann U, Young JP Jr. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain. 2008;12:203-213.
17. Gallagher RM. Naturalistic study designs in samples with refractory pain: advantages and limitations. Pain Med. 2004;5:143-145.
18. Berger A, Dukes EM, Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain. 2004;5:143-149.
19. McCarberg BH, Billington R. Consequences of neuropathic pain: quality-of-life issues and associated costs. Am J Manag Care. 2006;12(suppl 9):S263-S268.
20. Gálvez R, Rejas J, Pérez M, Gómez M. Prevalence of neuropathic pain in Spain: clinical, working and health care implications. Med Clin (Barc). 2005;125:221-229.
21. Martin BI, Deyo RA, Mirza SK, et al. Expenditures and health status among adults with back and neck problems. JAMA. 2008;299:656-664.
22. Pérez C, Gálvez R, Insausti J, Bennett M, Ruiz M, Rejas J. Group for the study of Spanish validation of LANSS. Linguistic adaptation and Spanish validation of the LANSS (Leeds Assessment of Neuropathic Symptoms and Signs) scale for the diagnosis of neuropathic pain. Med Clin (Barc). 2006;127:485-491.
23. Bermejo Velasco PE, Velasco Calvo R. New antiepileptic drugs and neuropathic pain. From molecular medicine to clinical practice. Med Clin (Barc). 2007;129:542-550.
24. van der Roer N, Goossens ME, Evers SM, van Tulder MW. What is the most cost-effective treatment for patients with low back pain? A systematic review. Best Pract Res Clin Rheumatol. 2005;19:671-684.
25. Saldaña MT, Navarro A, Pérez C, Masramon X, Rejas J. Health, non-health resources utilization and costs of treating refractory painful radiculopathy in Primary Care Settings (PCS) under routine medical practice in Spain. [abstract]. Value Health. 2007;10(suppl 6):A464.
26. Perez C, Galvez R, Huelbes S, et al. Validity and reliability of the Spanish version of the DN4 (Douleur Neuropathique 4 questions) questionnaire for differential diagnosis of pain syndromes associated to a neuropathic or somatic component. Health Qual Life Outcomes. 2007;5:66. doi: 10.1186/1477-7525-5-66.
27. Melzack R. The short-form McGill Pain Questionnaire. Pain. 1987;30: 191-197.
28. Catálogo de Especialidades Farmacéuticas 2006. Consejo General de Colegios Oficiales de Farmacéuticos, Madrid, 2006.
29. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004;110:628-638.
30. Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004;63:2104-2110.
31. Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebocontrolled trial. J Pain. 2005;6:253-260.
32. van Seventer R, Feister HA, Young JP Jr, Stoker M, Versavel M, Rigaudy L. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Curr Med Res Opin. 2006;22:375-384.
33. Gilron I, Watson CP, Cahill CM, Moulin DE. Neuropathic pain: a practical guide for the clinician. CMAJ. 2006;175:265-275.
34. Rodríguez MJ, García AJ. Costes del dolor neuropático según etiología en las Unidades del Dolor en españa. Rev Soc Esp Dolor. 2007;6:404-415.
35. Rodríguez MJ, Díaz S, Vera-Llonch M, Dukes E, Rejas J. Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. Curr Med Res Opin. 2007;23:2585-2596.
36. Tarride JE, Gordon A, Vera-Llonch M, Dukes E, Rousseau C. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective. Clin Ther. 2006;28:1922-1934.
37. Collet J, Boivin J. Bias and confounding in pharmacoepidemilolgy. In: Strom BL, ed. Pharmacoepidemiology. 3rd ed. U.K.: John Wiley & Sons; 2000:765-784.
38. Sommer M, Bachmann CG, Liebetanz KM, Schindehütte J, Tings T, Paulus W. Pregabalin in restless legs syndrome with and without neuropathic pain. Acta Neurol Scand. 2007;115:347-350.